- Home
- CABA vs RMR Comparison
CABA vs RMR Comparison
Compare CABA & RMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | RMR |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.1M | 312.9M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CABA | RMR |
|---|---|---|
| Price | $1.48 | $15.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $11.75 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 4.9M | 138.5K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 11.41% |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | N/A | ★ $700,284,000.00 |
| Revenue This Year | N/A | $221.97 |
| Revenue Next Year | N/A | $4.87 |
| P/E Ratio | ★ N/A | $16.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $14.73 |
| 52 Week High | $4.23 | $21.45 |
Technical Indicators
Market Signals| Indicator | CABA | RMR |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 29.32 |
| Support Level | N/A | $15.20 |
| Resistance Level | $1.63 | $20.52 |
| Average True Range (ATR) | 0.14 | 0.48 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 63.33 | 29.09 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
About RMR The RMR Group Inc.
The RMR Group Inc is a U.S. based real estate investment manager engaged in commercial real estate, private capital, and credit strategies. Its portfolio covers various commercial real estate asset classes, and it manages investments across various industries, geographies and asset classes.